Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01696045
Title Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Age Groups: child
Covered Countries USA | GBR | FRA | ESP | DEU | BEL

No variant requirements are available.